Back

Inflammation in obesity-related HFpEF: the STEP-HFpEF programme

30 August 2024 (08:26 - 08:37)
Organised by: Logo
Congress Presentation Part of: Clinical trial updates on the GLP-1 receptor agonist, semaglutide Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)

7 More presentations in this session

Presentation thumbnail
Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
STEP-HFpEF Program Echocardiography Substudy
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Effects of the GLP-1 receptor agonist, semaglutide, on heart failure outcomes: a pre-specified analysis of the FLOW trial in participants with type 2 diabetes and chronic kidney disease
Doctor R. Pratley (Orlando, US)
Slides Video
Presentation thumbnail
Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
Semaglutide and cardiovascular outcomes in females with overweight and obesity: A prespecified analysis of the SELECT trial
Professor S. Verma (Toronto, CA)
Slides Video

Access the full session

Session thumbnail
Clinical trial updates on the GLP-1 receptor agonist, semaglutide
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 08:26 CET
You may be interested in
thumbnail
Congress Presentation
Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials
thumbnail
Congress Presentation
Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials
thumbnail
Congress Presentation
Epicardial adipose tissue: a modulator of atrial fibrillation?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources